XML 36 R26.htm IDEA: XBRL DOCUMENT v3.7.0.1

Segment Information (Tables)

3 Months Ended

Mar. 31, 2017

Segment Reporting [Abstract]

Schedule of Information for the Company's Operating Segments

Information for the Company's reportable segments for the three months ended March 31, 2017 and 2016 are as follows:

Three Months Ended March 31, 2017	Consumer Operations			Drug Development		Corporate		Consolidated
Total revenue	$	242,547		—		—		$	242,547
Interest income, net	$	—		—		77,854		$	77,854
Loss from operations	$	1,987,810		3,828,281		2,530,158		$	8,346,249

Three Months Ended March 31, 2016	Consumer Operations			Drug Development		Corporate		Consolidated
Total revenue	$	—		—		—		$	—
Interest income, net	$	—		—		103,333		$	103,333
Loss from operations	$	2,929,355		4,059,043		2,707,396		$	9,695,794

X

- Definition

Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8924-108599

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8906-108599

+ Details

Name:	us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock
Namespace Prefix:	us-gaap_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	us-gaap_SegmentReportingAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration